Handelsbanken Fonder AB Decreases Stake in FibroGen (FGEN)

Handelsbanken Fonder AB reduced its holdings in FibroGen (NASDAQ:FGEN) by 17.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 164,000 shares of the biopharmaceutical company’s stock after selling 35,000 shares during the period. Handelsbanken Fonder AB’s holdings in FibroGen were worth $7,774,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Bank of Montreal Can lifted its stake in shares of FibroGen by 2,097.2% in the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. lifted its stake in shares of FibroGen by 95.0% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 1,700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of FibroGen by 41.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 1,147 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its stake in shares of FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 2,336 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new position in shares of FibroGen in the fourth quarter worth about $255,000. 61.39% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

FibroGen (NASDAQ:FGEN) opened at $48.90 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. FibroGen has a 52 week low of $22.75 and a 52 week high of $63.00. The company has a market cap of $4,220.15, a PE ratio of -27.63 and a beta of 1.76.

In other FibroGen news, insider K Peony Yu sold 10,000 shares of FibroGen stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $62.00, for a total transaction of $620,000.00. Following the transaction, the insider now directly owns 152,086 shares of the company’s stock, valued at $9,429,332. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $47.38, for a total transaction of $284,280.00. Following the transaction, the director now directly owns 28,000 shares in the company, valued at $1,326,640. The disclosure for this sale can be found here. Insiders have sold 484,335 shares of company stock worth $25,751,760 over the last ninety days. 13.60% of the stock is owned by insiders.

Several equities analysts have recently weighed in on the stock. TheStreet raised shares of FibroGen from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Leerink Swann reaffirmed an “outperform” rating and set a $88.00 target price (up from $80.00) on shares of FibroGen in a research note on Wednesday, February 28th. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Finally, BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. FibroGen currently has an average rating of “Hold” and an average price target of $66.67.

TRADEMARK VIOLATION NOTICE: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3293868/handelsbanken-fonder-ab-decreases-stake-in-fibrogen-fgen.html.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

First Foundation  Stock Rating Upgraded by BidaskClub
First Foundation Stock Rating Upgraded by BidaskClub
Comcast  Stock Rating Upgraded by BidaskClub
Comcast Stock Rating Upgraded by BidaskClub
$0.04 EPS Expected for Iridium Communications  This Quarter
$0.04 EPS Expected for Iridium Communications This Quarter
$0.13 EPS Expected for Magic Software Enterprises  This Quarter
$0.13 EPS Expected for Magic Software Enterprises This Quarter
Building Materials Holding Co.  Expected to Announce Earnings of $0.12 Per Share
Building Materials Holding Co. Expected to Announce Earnings of $0.12 Per Share
AGNC Investment Corp.  to Issue Apr 18 Dividend of $0.18 on  May 9th
AGNC Investment Corp. to Issue Apr 18 Dividend of $0.18 on May 9th


© 2006-2018 Ticker Report. Google+.